- Home
- CADL vs GEVO Comparison
CADL vs GEVO Comparison
Compare CADL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | GEVO |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 470.1M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CADL | GEVO |
|---|---|---|
| Price | $4.76 | $2.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $19.43 | $8.13 |
| AVG Volume (30 Days) | 663.0K | ★ 3.7M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $120,932,000.00 |
| Revenue This Year | N/A | $909.99 |
| Revenue Next Year | N/A | $11.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 675.75 |
| 52 Week Low | $4.25 | $0.92 |
| 52 Week High | $14.60 | $2.98 |
Technical Indicators
Market Signals| Indicator | CADL | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 51.29 |
| Support Level | $4.35 | $1.83 |
| Resistance Level | $4.68 | $2.04 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.78 | 64.77 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.